“Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”, J of Skin, vol. 3, no. 2, p. 175, Mar. 2019, doi: 10.25251/skin.3.2.15.